Indaptus Therapeutics (INDP) Enterprise Value (2020 - 2026)

Indaptus Therapeutics' Enterprise Value history runs 7 years deep, the most recent figure standing at -$1.5 million for Q1 2026.

• In Q1 2026, Enterprise Value rose 61.51% year-over-year to -$1.5 million; the TTM figure through Mar 2026 stood at -$1.5 million (up 61.51% YoY), while the FY2025 annual figure was -$8.5 million, down 47.02% from the prior year.
• Enterprise Value for Q1 2026 stood at -$1.5 million, up from -$8.5 million in the prior quarter.
• The five-year high for Enterprise Value was -$1.5 million in Q1 2026, with the low at -$36.2 million in Q1 2022.
• The 5-year median for Enterprise Value is -$9.7 million (2024), against an average of -$14.8 million.
• The sharpest annual moves came in 2022 and 2024: Enterprise Value sank 224.9% in 2022, then jumped 62.92% in 2024.
• Indaptus Therapeutics' Enterprise Value stood at -$26.4 million in 2022, then soared by 49.45% to -$13.4 million in 2023, then surged by 56.69% to -$5.8 million in 2024, then slumped by 47.02% to -$8.5 million in 2025, then surged by 82.4% to -$1.5 million in 2026.
• Business Quant data shows INDP's Enterprise Value at -$1.5 million in Q1 2026, -$8.5 million in Q4 2025, and -$5.8 million in Q3 2025.